108 related articles for article (PubMed ID: 17224206)
1. Gorse GJ, et al. "Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial" [Vaccine 24 (2006) 5950-5959].
Zink TK
Vaccine; 2007 Apr; 25(15):2766-7. PubMed ID: 17224206
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
[TBL] [Abstract][Full Text] [Related]
3. Results of a safety and immunogenicity study of an early-stage investigational rPA102 vaccine as compared to the FDA licensed anthrax vaccine (anthrax vaccine adsorbed (AVA. BioThrax)).
Hannesschlager JR
Vaccine; 2007 Apr; 25(17):3247. PubMed ID: 17234308
[No Abstract] [Full Text] [Related]
4. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
[TBL] [Abstract][Full Text] [Related]
5. Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG.
Semenova VA; Schiffer J; Steward-Clark E; Soroka S; Schmidt DS; Brawner MM; Lyde F; Thompson R; Brown N; Foster L; Fox S; Patel N; Freeman AE; Quinn CP
J Immunol Methods; 2012 Feb; 376(1-2):97-107. PubMed ID: 22197974
[TBL] [Abstract][Full Text] [Related]
6. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109.
Gu M; Hine PM; James Jackson W; Giri L; Nabors GS
Vaccine; 2007 Jan; 25(3):526-34. PubMed ID: 16973247
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.
Hopkins RJ; Daczkowski NF; Kaptur PE; Muse D; Sheldon E; LaForce C; Sari S; Rudge TL; Bernton E
Vaccine; 2013 Jun; 31(30):3051-8. PubMed ID: 23701746
[TBL] [Abstract][Full Text] [Related]
8. Licensure strategy for pre- and post-exposure prophylaxis of biothrax vaccine: the first vaccine licensed using the FDA animal rule.
Longstreth J; Skiadopoulos MH; Hopkins RJ
Expert Rev Vaccines; 2016 Dec; 15(12):1467-1479. PubMed ID: 27792416
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.
Hopkins RJ; Kalsi G; Montalvo-Lugo VM; Sharma M; Wu Y; Muse DD; Sheldon EA; Hampel FC; Lemiale L
Vaccine; 2016 Apr; 34(18):2096-105. PubMed ID: 26979136
[TBL] [Abstract][Full Text] [Related]
10. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans.
Pittman PR; Kim-Ahn G; Pifat DY; Coonan K; Gibbs P; Little S; Pace-Templeton JG; Myers R; Parker GW; Friedlander AM
Vaccine; 2002 Jan; 20(9-10):1412-20. PubMed ID: 11818160
[TBL] [Abstract][Full Text] [Related]
11. Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.
Semenova VA; Schmidt DS; Taylor TH; Li H; Steward-Clark E; Soroka SD; Ballard MM; Quinn CP
Vaccine; 2007 Feb; 25(10):1780-8. PubMed ID: 17229495
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program.
Fowler GL; Baggs JM; Weintraub ES; Martin SW; McNeil MM; Gust DA
Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):880-8. PubMed ID: 16924600
[TBL] [Abstract][Full Text] [Related]
13. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; Ward BJ; West DJ
Pharmacoepidemiol Drug Saf; 2004 Dec; 13(12):825-40. PubMed ID: 15386719
[TBL] [Abstract][Full Text] [Related]
14. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial.
Marano N; Plikaytis BD; Martin SW; Rose C; Semenova VA; Martin SK; Freeman AE; Li H; Mulligan MJ; Parker SD; Babcock J; Keitel W; El Sahly H; Poland GA; Jacobson RM; Keyserling HL; Soroka SD; Fox SP; Stamper JL; McNeil MM; Perkins BA; Messonnier N; Quinn CP;
JAMA; 2008 Oct; 300(13):1532-43. PubMed ID: 18827210
[TBL] [Abstract][Full Text] [Related]
15. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals.
Hewetson JF; Little SF; Ivins BE; Johnson WM; Pittman PR; Brown JE; Norris SL; Nielsen CJ
Vaccine; 2008 Aug; 26(33):4262-6. PubMed ID: 18586363
[TBL] [Abstract][Full Text] [Related]
16. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial.
Wright JG; Plikaytis BD; Rose CE; Parker SD; Babcock J; Keitel W; El Sahly H; Poland GA; Jacobson RM; Keyserling HL; Semenova VA; Li H; Schiffer J; Dababneh H; Martin SK; Martin SW; Marano N; Messonnier NE; Quinn CP
Vaccine; 2014 Feb; 32(8):1019-28. PubMed ID: 24373307
[TBL] [Abstract][Full Text] [Related]
17. Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.
Skoura N; Wang-Jairaj J; Della Pasqua O; Chandrasekaran V; Billiard J; Yeakey A; Smith W; Steel H; Tan LK
Lancet Infect Dis; 2020 Aug; 20(8):983-991. PubMed ID: 32333847
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of anthrax vaccine safety in 18 to 20 year olds: A first step towards age de-escalation studies in adolescents.
King JC; Gao Y; Quinn CP; Dreier TM; Vianney C; Espeland EM
Vaccine; 2015 May; 33(21):2470-6. PubMed ID: 25850022
[TBL] [Abstract][Full Text] [Related]
19. Biodefense. New anthrax vaccine gets a green light.
Enserink M; Marshall E
Science; 2002 Apr; 296(5568):639-40. PubMed ID: 11976419
[No Abstract] [Full Text] [Related]
20. Immunogenicity of a subunit vaccine against Bacillus anthracis.
Chichester JA; Musiychuk K; de la Rosa P; Horsey A; Stevenson N; Ugulava N; Rabindran S; Palmer GA; Mett V; Yusibov V
Vaccine; 2007 Apr; 25(16):3111-4. PubMed ID: 17280756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
